Eintrag weiter verarbeiten
Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance
Gespeichert in:
Zeitschriftentitel: | Journal of Gastroenterology and Hepatology |
---|---|
Personen und Körperschaften: | , , , , , , , , |
In: | Journal of Gastroenterology and Hepatology, 23, 2008, 2, S. 244-251 |
Medientyp: | E-Article |
Sprache: | Englisch |
veröffentlicht: |
Wiley
|
Schlagwörter: |
author_facet |
Itou, Minoru Kawaguchi, Takumi Taniguchi, Eitaro Sumie, Shuji Oriishi, Tetsuharu Mitsuyama, Keiichi Tsuruta, Osamu Ueno, Takato Sata, Michio Itou, Minoru Kawaguchi, Takumi Taniguchi, Eitaro Sumie, Shuji Oriishi, Tetsuharu Mitsuyama, Keiichi Tsuruta, Osamu Ueno, Takato Sata, Michio |
---|---|
author |
Itou, Minoru Kawaguchi, Takumi Taniguchi, Eitaro Sumie, Shuji Oriishi, Tetsuharu Mitsuyama, Keiichi Tsuruta, Osamu Ueno, Takato Sata, Michio |
spellingShingle |
Itou, Minoru Kawaguchi, Takumi Taniguchi, Eitaro Sumie, Shuji Oriishi, Tetsuharu Mitsuyama, Keiichi Tsuruta, Osamu Ueno, Takato Sata, Michio Journal of Gastroenterology and Hepatology Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance Gastroenterology Hepatology |
author_sort |
itou, minoru |
spelling |
Itou, Minoru Kawaguchi, Takumi Taniguchi, Eitaro Sumie, Shuji Oriishi, Tetsuharu Mitsuyama, Keiichi Tsuruta, Osamu Ueno, Takato Sata, Michio 0815-9319 1440-1746 Wiley Gastroenterology Hepatology http://dx.doi.org/10.1111/j.1440-1746.2007.05183.x <jats:title>Abstract</jats:title><jats:p><jats:bold>Background and Aim: </jats:bold> The pathogenesis of hepatitis C virus (HCV)‐associated glucose intolerance remains unclear. Glucagon‐like peptide‐1 (GLP‐1), a gut hormone, synthesizes hepatic glycogen and is inactivated by dipeptidyl peptidase IV (DPPIV). The aims of this study were to investigate the alterations in the expression of GLP‐1 and DPPIV in HCV‐associated glucose intolerance.</jats:p><jats:p><jats:bold>Methods: </jats:bold> We enrolled patients with HCV‐ or hepatitis B virus (HBV)‐related liver disease (<jats:italic>n</jats:italic> = 94 and 37, respectively), patients with inflammatory bowel disease (IBD; <jats:italic>n</jats:italic> = 14) as disease controls, and healthy controls (<jats:italic>n</jats:italic> = 48). The serum or tissue GLP‐1 and DPPIV expression levels were determined by enzyme immunoassay, immunoblotting, or immunostaining. The hepatic glycogen content was assayed by periodic acid–Schiff staining.</jats:p><jats:p><jats:bold>Results: </jats:bold> The serum GLP‐1 levels were significantly decreased in the HCV group (4.9 ± 0.3 ng/mL) than those in the controls (7.5 ± 0.6 ng/mL), the HBV group (7.0 ± 0.5 ng/mL), or the IBD group (10.8 ± 1.0 ng/mL, <jats:italic>P</jats:italic> < 0.01). Although the ileum GLP‐1 expression was not significantly different between the controls and the HCV group, the DPPIV expression was significantly increased in the ileum, liver, and serum in the HCV group. Hepatic glycogen content was decreased to a greater extent in the HCV group than that in the HBV group (127.5 ± 5.3 <jats:italic>vs</jats:italic> 187.7 ± 6.6 arbitrary units; <jats:italic>n</jats:italic> = 19, <jats:italic>P</jats:italic> < 0.01).</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> We demonstrated the altered expressions of GLP‐1 and DPPIV in patients with HCV‐associated glucose intolerance. Since hepatic glycogen synthesis, a GLP‐1 action, was impaired, the altered expressions of GLP‐1 and DPPIV may be involved in the development of HCV‐associated glucose intolerance.</jats:p> Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance Journal of Gastroenterology and Hepatology |
doi_str_mv |
10.1111/j.1440-1746.2007.05183.x |
facet_avail |
Online |
finc_class_facet |
Medizin |
format |
ElectronicArticle |
fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE0NDAtMTc0Ni4yMDA3LjA1MTgzLng |
id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE0NDAtMTc0Ni4yMDA3LjA1MTgzLng |
institution |
DE-Brt1 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 |
imprint |
Wiley, 2008 |
imprint_str_mv |
Wiley, 2008 |
issn |
0815-9319 1440-1746 |
issn_str_mv |
0815-9319 1440-1746 |
language |
English |
mega_collection |
Wiley (CrossRef) |
match_str |
itou2008alteredexpressionofglucagonlikepeptide1anddipeptidylpeptidaseivinpatientswithhcvrelatedglucoseintolerance |
publishDateSort |
2008 |
publisher |
Wiley |
recordtype |
ai |
record_format |
ai |
series |
Journal of Gastroenterology and Hepatology |
source_id |
49 |
title |
Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_unstemmed |
Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_full |
Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_fullStr |
Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_full_unstemmed |
Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_short |
Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_sort |
altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase iv in patients with hcv‐related glucose intolerance |
topic |
Gastroenterology Hepatology |
url |
http://dx.doi.org/10.1111/j.1440-1746.2007.05183.x |
publishDate |
2008 |
physical |
244-251 |
description |
<jats:title>Abstract</jats:title><jats:p><jats:bold>Background and Aim: </jats:bold> The pathogenesis of hepatitis C virus (HCV)‐associated glucose intolerance remains unclear. Glucagon‐like peptide‐1 (GLP‐1), a gut hormone, synthesizes hepatic glycogen and is inactivated by dipeptidyl peptidase IV (DPPIV). The aims of this study were to investigate the alterations in the expression of GLP‐1 and DPPIV in HCV‐associated glucose intolerance.</jats:p><jats:p><jats:bold>Methods: </jats:bold> We enrolled patients with HCV‐ or hepatitis B virus (HBV)‐related liver disease (<jats:italic>n</jats:italic> = 94 and 37, respectively), patients with inflammatory bowel disease (IBD; <jats:italic>n</jats:italic> = 14) as disease controls, and healthy controls (<jats:italic>n</jats:italic> = 48). The serum or tissue GLP‐1 and DPPIV expression levels were determined by enzyme immunoassay, immunoblotting, or immunostaining. The hepatic glycogen content was assayed by periodic acid–Schiff staining.</jats:p><jats:p><jats:bold>Results: </jats:bold> The serum GLP‐1 levels were significantly decreased in the HCV group (4.9 ± 0.3 ng/mL) than those in the controls (7.5 ± 0.6 ng/mL), the HBV group (7.0 ± 0.5 ng/mL), or the IBD group (10.8 ± 1.0 ng/mL, <jats:italic>P</jats:italic> < 0.01). Although the ileum GLP‐1 expression was not significantly different between the controls and the HCV group, the DPPIV expression was significantly increased in the ileum, liver, and serum in the HCV group. Hepatic glycogen content was decreased to a greater extent in the HCV group than that in the HBV group (127.5 ± 5.3 <jats:italic>vs</jats:italic> 187.7 ± 6.6 arbitrary units; <jats:italic>n</jats:italic> = 19, <jats:italic>P</jats:italic> < 0.01).</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> We demonstrated the altered expressions of GLP‐1 and DPPIV in patients with HCV‐associated glucose intolerance. Since hepatic glycogen synthesis, a GLP‐1 action, was impaired, the altered expressions of GLP‐1 and DPPIV may be involved in the development of HCV‐associated glucose intolerance.</jats:p> |
container_issue |
2 |
container_start_page |
244 |
container_title |
Journal of Gastroenterology and Hepatology |
container_volume |
23 |
format_de105 |
Article, E-Article |
format_de14 |
Article, E-Article |
format_de15 |
Article, E-Article |
format_de520 |
Article, E-Article |
format_de540 |
Article, E-Article |
format_dech1 |
Article, E-Article |
format_ded117 |
Article, E-Article |
format_degla1 |
E-Article |
format_del152 |
Buch |
format_del189 |
Article, E-Article |
format_dezi4 |
Article |
format_dezwi2 |
Article, E-Article |
format_finc |
Article, E-Article |
format_nrw |
Article, E-Article |
_version_ |
1792337463921868802 |
geogr_code |
not assigned |
last_indexed |
2024-03-01T15:16:45Z |
geogr_code_person |
not assigned |
openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Altered+expression+of+glucagon%E2%80%90like+peptide%E2%80%901+and+dipeptidyl+peptidase+IV+in+patients+with+HCV%E2%80%90related+glucose+intolerance&rft.date=2008-02-01&genre=article&issn=1440-1746&volume=23&issue=2&spage=244&epage=251&pages=244-251&jtitle=Journal+of+Gastroenterology+and+Hepatology&atitle=Altered+expression+of+glucagon%E2%80%90like+peptide%E2%80%901+and+dipeptidyl+peptidase+IV+in+patients+with+HCV%E2%80%90related+glucose+intolerance&aulast=Sata&aufirst=Michio&rft_id=info%3Adoi%2F10.1111%2Fj.1440-1746.2007.05183.x&rft.language%5B0%5D=eng |
SOLR | |
_version_ | 1792337463921868802 |
author | Itou, Minoru, Kawaguchi, Takumi, Taniguchi, Eitaro, Sumie, Shuji, Oriishi, Tetsuharu, Mitsuyama, Keiichi, Tsuruta, Osamu, Ueno, Takato, Sata, Michio |
author_facet | Itou, Minoru, Kawaguchi, Takumi, Taniguchi, Eitaro, Sumie, Shuji, Oriishi, Tetsuharu, Mitsuyama, Keiichi, Tsuruta, Osamu, Ueno, Takato, Sata, Michio, Itou, Minoru, Kawaguchi, Takumi, Taniguchi, Eitaro, Sumie, Shuji, Oriishi, Tetsuharu, Mitsuyama, Keiichi, Tsuruta, Osamu, Ueno, Takato, Sata, Michio |
author_sort | itou, minoru |
container_issue | 2 |
container_start_page | 244 |
container_title | Journal of Gastroenterology and Hepatology |
container_volume | 23 |
description | <jats:title>Abstract</jats:title><jats:p><jats:bold>Background and Aim: </jats:bold> The pathogenesis of hepatitis C virus (HCV)‐associated glucose intolerance remains unclear. Glucagon‐like peptide‐1 (GLP‐1), a gut hormone, synthesizes hepatic glycogen and is inactivated by dipeptidyl peptidase IV (DPPIV). The aims of this study were to investigate the alterations in the expression of GLP‐1 and DPPIV in HCV‐associated glucose intolerance.</jats:p><jats:p><jats:bold>Methods: </jats:bold> We enrolled patients with HCV‐ or hepatitis B virus (HBV)‐related liver disease (<jats:italic>n</jats:italic> = 94 and 37, respectively), patients with inflammatory bowel disease (IBD; <jats:italic>n</jats:italic> = 14) as disease controls, and healthy controls (<jats:italic>n</jats:italic> = 48). The serum or tissue GLP‐1 and DPPIV expression levels were determined by enzyme immunoassay, immunoblotting, or immunostaining. The hepatic glycogen content was assayed by periodic acid–Schiff staining.</jats:p><jats:p><jats:bold>Results: </jats:bold> The serum GLP‐1 levels were significantly decreased in the HCV group (4.9 ± 0.3 ng/mL) than those in the controls (7.5 ± 0.6 ng/mL), the HBV group (7.0 ± 0.5 ng/mL), or the IBD group (10.8 ± 1.0 ng/mL, <jats:italic>P</jats:italic> < 0.01). Although the ileum GLP‐1 expression was not significantly different between the controls and the HCV group, the DPPIV expression was significantly increased in the ileum, liver, and serum in the HCV group. Hepatic glycogen content was decreased to a greater extent in the HCV group than that in the HBV group (127.5 ± 5.3 <jats:italic>vs</jats:italic> 187.7 ± 6.6 arbitrary units; <jats:italic>n</jats:italic> = 19, <jats:italic>P</jats:italic> < 0.01).</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> We demonstrated the altered expressions of GLP‐1 and DPPIV in patients with HCV‐associated glucose intolerance. Since hepatic glycogen synthesis, a GLP‐1 action, was impaired, the altered expressions of GLP‐1 and DPPIV may be involved in the development of HCV‐associated glucose intolerance.</jats:p> |
doi_str_mv | 10.1111/j.1440-1746.2007.05183.x |
facet_avail | Online |
finc_class_facet | Medizin |
format | ElectronicArticle |
format_de105 | Article, E-Article |
format_de14 | Article, E-Article |
format_de15 | Article, E-Article |
format_de520 | Article, E-Article |
format_de540 | Article, E-Article |
format_dech1 | Article, E-Article |
format_ded117 | Article, E-Article |
format_degla1 | E-Article |
format_del152 | Buch |
format_del189 | Article, E-Article |
format_dezi4 | Article |
format_dezwi2 | Article, E-Article |
format_finc | Article, E-Article |
format_nrw | Article, E-Article |
geogr_code | not assigned |
geogr_code_person | not assigned |
id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTExMS9qLjE0NDAtMTc0Ni4yMDA3LjA1MTgzLng |
imprint | Wiley, 2008 |
imprint_str_mv | Wiley, 2008 |
institution | DE-Brt1, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3 |
issn | 0815-9319, 1440-1746 |
issn_str_mv | 0815-9319, 1440-1746 |
language | English |
last_indexed | 2024-03-01T15:16:45Z |
match_str | itou2008alteredexpressionofglucagonlikepeptide1anddipeptidylpeptidaseivinpatientswithhcvrelatedglucoseintolerance |
mega_collection | Wiley (CrossRef) |
physical | 244-251 |
publishDate | 2008 |
publishDateSort | 2008 |
publisher | Wiley |
record_format | ai |
recordtype | ai |
series | Journal of Gastroenterology and Hepatology |
source_id | 49 |
spelling | Itou, Minoru Kawaguchi, Takumi Taniguchi, Eitaro Sumie, Shuji Oriishi, Tetsuharu Mitsuyama, Keiichi Tsuruta, Osamu Ueno, Takato Sata, Michio 0815-9319 1440-1746 Wiley Gastroenterology Hepatology http://dx.doi.org/10.1111/j.1440-1746.2007.05183.x <jats:title>Abstract</jats:title><jats:p><jats:bold>Background and Aim: </jats:bold> The pathogenesis of hepatitis C virus (HCV)‐associated glucose intolerance remains unclear. Glucagon‐like peptide‐1 (GLP‐1), a gut hormone, synthesizes hepatic glycogen and is inactivated by dipeptidyl peptidase IV (DPPIV). The aims of this study were to investigate the alterations in the expression of GLP‐1 and DPPIV in HCV‐associated glucose intolerance.</jats:p><jats:p><jats:bold>Methods: </jats:bold> We enrolled patients with HCV‐ or hepatitis B virus (HBV)‐related liver disease (<jats:italic>n</jats:italic> = 94 and 37, respectively), patients with inflammatory bowel disease (IBD; <jats:italic>n</jats:italic> = 14) as disease controls, and healthy controls (<jats:italic>n</jats:italic> = 48). The serum or tissue GLP‐1 and DPPIV expression levels were determined by enzyme immunoassay, immunoblotting, or immunostaining. The hepatic glycogen content was assayed by periodic acid–Schiff staining.</jats:p><jats:p><jats:bold>Results: </jats:bold> The serum GLP‐1 levels were significantly decreased in the HCV group (4.9 ± 0.3 ng/mL) than those in the controls (7.5 ± 0.6 ng/mL), the HBV group (7.0 ± 0.5 ng/mL), or the IBD group (10.8 ± 1.0 ng/mL, <jats:italic>P</jats:italic> < 0.01). Although the ileum GLP‐1 expression was not significantly different between the controls and the HCV group, the DPPIV expression was significantly increased in the ileum, liver, and serum in the HCV group. Hepatic glycogen content was decreased to a greater extent in the HCV group than that in the HBV group (127.5 ± 5.3 <jats:italic>vs</jats:italic> 187.7 ± 6.6 arbitrary units; <jats:italic>n</jats:italic> = 19, <jats:italic>P</jats:italic> < 0.01).</jats:p><jats:p><jats:bold>Conclusion: </jats:bold> We demonstrated the altered expressions of GLP‐1 and DPPIV in patients with HCV‐associated glucose intolerance. Since hepatic glycogen synthesis, a GLP‐1 action, was impaired, the altered expressions of GLP‐1 and DPPIV may be involved in the development of HCV‐associated glucose intolerance.</jats:p> Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance Journal of Gastroenterology and Hepatology |
spellingShingle | Itou, Minoru, Kawaguchi, Takumi, Taniguchi, Eitaro, Sumie, Shuji, Oriishi, Tetsuharu, Mitsuyama, Keiichi, Tsuruta, Osamu, Ueno, Takato, Sata, Michio, Journal of Gastroenterology and Hepatology, Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance, Gastroenterology, Hepatology |
title | Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_full | Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_fullStr | Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_full_unstemmed | Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_short | Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
title_sort | altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase iv in patients with hcv‐related glucose intolerance |
title_unstemmed | Altered expression of glucagon‐like peptide‐1 and dipeptidyl peptidase IV in patients with HCV‐related glucose intolerance |
topic | Gastroenterology, Hepatology |
url | http://dx.doi.org/10.1111/j.1440-1746.2007.05183.x |